S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
-
- H. Erba
- Duke Cancer Institute, Durham, NC, United States of America
-
- P. Montesinos
- La Fe University and Polytechnic Hospital, Valencia, Spain
-
- R. Vrhovac
- University Hospital Centre Zagreb, Zagreb, Croatia
-
- E. Patkowska
- Institute of Hematology and Blood Transfusion, Warsaw, Poland
-
- H.-J. Kim
- The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea
-
- P. Zak
- University Hospital Hradec Kralove, Hradec Kralove, Czechia
-
- P.-N. Wang
- Chang Gung Medical Foundation, Linkou, Taiwan
-
- T. Mitov
- Daiichi Sankyo UK Ltd, Uxbridge, United Kingdom
-
- J. Hanyok
- Daiichi Sankyo, Inc, Basking Ridge, NJ
-
- L. Liu
- Daiichi Sankyo, Inc, Basking Ridge, NJ
-
- A. Benzohra
- Daiichi Sankyo, Inc, Basking Ridge, NJ
-
- A. Lesegretain
- Daiichi Sankyo, Inc, Basking Ridge, NJ
-
- J. Cortes
- Augusta University Medical Center, Augusta, GA
-
- A. Perl
- University of Pennsylvania, Philadelphia, PA
-
- M. Sekeres
- University of Miami Health System, Miami, FL, United States of America
-
- H. Dombret
- Saint Louis Hospital, University of Paris, Paris, France
-
- S. Amadori
- Tor Vergata Polyclinic Hospital Rome, Rome, Italy
-
- J. Wang
- Institute of Hematology and Blood Diseases Hospital, Tianjin, China
-
- M. Levis
- Johns Hopkins University, Baltimore, MD, United States of America
-
- R. Schlenk
- Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
収録刊行物
-
- HemaSphere
-
HemaSphere 6 1-2, 2022-06
Wiley